Comments

Regeneron Pharmaceuticals Stock Price, Quotes and Forecasts

Q: What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

REGNNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$706.94

-16.53-2.28%

At close: -

$706.94

0.000.00%

After Hours: 4:00 PM EDT

The dividend Ex-Date was 7 days ago

Regeneron Pharmaceuticals (REGN) Forecast

News Earnings Regeneron Pharmaceuticals (REGN) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Edge Rankings

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings

Regeneron Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:REGN | Benzinga

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN.

Open	$721.29
Close	$706.94
Volume / Avg.	713.05K / 892.01K
Day Range	$701.07 - $721.41
52 Wk Range	642.00 - 1.21K
Market Cap	$77.69B
P/E Ratio	18.87
Dividend Yield	0.49%
Exchange	NASDAQ
RSI	53
Short Interest	2.1%
Days to Cover	2.4

Recent News

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.

Vandana Singh

Biogen Stock Is Mutating Into a Value Play

([content-module:CompanyOverview, NASDAQ:BIIB) Biogen Inc. (NASDAQ:BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical

MarketBeat

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Dec 24

Jan

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$721.29
Close	$706.94
Volume / Avg.	713.05K / 892.01K
Day Range	$701.07 - $721.41
52 Wk Range	642.00 - 1.21K
Market Cap	$77.69B
P/E Ratio	18.87
Dividend Yield	0.49%
Exchange	NASDAQ
RSI	53
Short Interest	2.1%
Days to Cover	2.4

About Regeneron Pharmaceuticals, Inc.

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye diseas...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Regeneron Pharmaceuticals (REGN) stock?

You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.

View our list of the best stock brokerages

Who are Regeneron Pharmaceuticals (REGN) competitors?

Other companies in Regeneron Pharmaceuticals’s space includes: Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), BeiGene (NASDAQ:ONC), Neurocrine Biosciences (NASDAQ:NBIX) and Roivant Sciences (NASDAQ:ROIV).

What is the forecast, or price target, for Regeneron Pharmaceuticals (REGN) stock?

Regeneron Pharmaceuticals has a consensus price target of $972.68.

What is the current price for Regeneron Pharmaceuticals (REGN)?

The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $706.94 last updated February 26, 2025 at 4:00 PM EST.

Does Regeneron Pharmaceuticals (REGN) pay a dividend?

A quarterly cash dividend of 0.88 per share of Class A Common Stock. The quarterly cash dividend was payable on March 20, 2025 to stockholders of record on February 20, 2025.

When is Regeneron Pharmaceuticals (NASDAQ:REGN) reporting earnings?

Regeneron Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 1, 2025.

Is Regeneron Pharmaceuticals (REGN) going to split?

There is no upcoming split for Regeneron Pharmaceuticals.

What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.